Maxim Group analyst Michael Okunewitch has maintained their bullish stance on OCGN stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Okunewitch has given his Buy rating due to a combination of factors related to Ocugen’s promising clinical progress and strategic positioning. The company is advancing its pivotal studies for OCU400 in retinitis pigmentosa and OCU410ST in Stargardt disease, both of which are nearing completion of enrollment. This progress is expected to lead to significant data releases in 2026, which could act as catalysts for the stock.
Additionally, Ocugen’s approach to clinical trials, which includes the use of placebo control arms, aligns well with regulatory expectations, potentially reducing the risk of regulatory hurdles. The company’s financial position is also stable, with enough cash to fund operations into the second quarter of 2026. Furthermore, the recent regulatory developments in the ophthalmic space, such as the UK’s acceptance of a Conditional Marketing Authorization application for a similar treatment, suggest a favorable environment for Ocugen’s future filings. These factors, combined with Ocugen’s ambitious goal of targeting three BLA filings in three years, underpin the positive outlook and the increased price target of $8.00.
In another report released today, Noble Financial also reiterated a Buy rating on the stock with a $8.00 price target.
OCGN’s price has also changed dramatically for the past six months – from $0.715 to $1.380, which is a 93.01% increase.